Solárová Zuzana, Mojžiš Ján, Solár Peter: Hsp90 inhibitor as a sensitizer of cancer cells to different therapies. International Journal of Oncology. - ISSN 1019-6439. - Vol. 46, no. 3 (2015), s. 907-926. ADC - Vedecké práce v zahraničných karentovaných časopisoch IF 3,018, Q2-SJR, citované 49x

Basic data
OCA1. Surname awarded to the assessed person	Solárová
OCA2. Name awarded to the assessed person	Zuzana
OCA3. Degrees awarded to the assessed person	Assoc. prof. , M.D., PhD
OCA4. Hyperlink to the entry of the person in the Register of university staff	https://www.portalvs.sk/regzam/detail/15120?mode=full
OCA5. Area of assessment	study programme pharmacy (joint study programme) · I. + II. degree
OCA6. Category of the research/artistic/other output	scientific output
OCA7. Year of publication of the research/artistic/other output	2015
OCA8. ID of the record in the Central Registry of Publication Activity (CRPA) or the Central Registry of Artistic Activity (CRAA)
OCA9. Hyperlink to the record in CRPA or CRAA	http://www.crepc.sk/portal?fn=*recview&uid=1681828&pageId=resultform&full=0
Characteristics of the output that is not registered in CRPA or CRAA
OCA10. Hyperlink to the record in another publicly accessible register, catalogue of research/ artistic/other outputs
OCA11. Characteristics of the output in the format of the CRPA or the CRAA bibliographic record, if the output is not available in a publicly accessible register or catalogue of outputs	Solárová Zuzana, Mojžiš Ján, Solár Peter: Hsp90 inhibitor as a sensitizer of cancer cells to different therapies. International Journal of Oncology. - ISSN 1019-6439. - Vol. 46, no. 3 (2015), s. 907-926. ADC - Vedecké práce v zahraničných karentovaných časopisoch IF 3,018, Q2-SJR, citované 49x
OCA12. Type of the output (if the output is not registered in CRPA or CRAA)	article
OCA13. Hyperlink to the webpage where the output is available (full text, other documentation, etc.)
OCA14. Characteristics of the author's contribution	SOLÁROVÁ, Zuzana (75%) - MOJŽIŠ, Ján (15%) - SOLÁR, Peter (10%)
OCA15. Annotation of the output with contextual information concerning the description of creative process and the content of the research/artistic/other activity, etc.
Other data
OCA16. Annotation of the output in English	Hsp90 is a molecular chaperone that maintains the structural and functional integrity of various client proteins involved in signaling and many other functions of cancer cells. The natural inhibitors, ansamycins influence the Hsp90 chaperone function by preventing its binding to client proteins and resulting in their proteasomal degradation. N- and C-terminal inhibitors of Hsp90 and their analogues are widely tested as potential anticancer agents in vitro, in vivo as well as in clinical trials. It seems that Hsp90 competitive inhibitors target different tumor types at nanomolar concentrations and might have therapeutic benefit. On the contrary, some Hsp90 inhibitors increased toxicity and resistance of cancer cells induced by heat shock response, and through the interaction of survival signals, that occured as side effects of treatments, could be very effectively limited via combination of therapies. The aim of our review was to collect the data from experimental and clinical trials where Hsp90 inhibitor was combined with other therapies in order to prevent resistance as well as to potentiate the cytotoxic and/or antiproliferative effects.
OCA17. List of maximum 5 most significant citations corresponding to the output	ZAVAREH, R.B. et al. HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins. In Cell Chemical Biology, 2021, doi: 10.1016/j.chembiol.2020.10.005. (IF=8,116) SHERIN, D.R., MANOJKUMAR, T.K. Exploring the selectivity of guanine scaffold in anticancer drug development by computational repurposing approach. In Scientific Reports, 2021, vol. 11, no. 1, art. no. 16251, doi: 10.1038/s41598-021-95507-4. (IF 4,379) LIU, Y.-M. et al. Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo. In European Journal of Medicinal Chemistry, 2021, vol. 219, art. no. 113428. doi: 10.1016/j.ejmech.2021.113428. (IF=6,514) DEBELE, T.A. et al. Transferrin modified gsh sensitive hyaluronic acid derivative micelle to deliver hsp90 inhibitors to enhance the therapeutic efficacy of brain cancers. In Cancers, 2021, vol. 13, no. 10, art. no. 2375, doi: 10.3390/cancers13102375. (IF=6,639) ABOU-SERI, S.M. et al. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2. In Bioorganic Chemistry, 2021, vol. 116, art. no. 105334. doi: 10.1016/j.bioorg.2021.105334. (IF=5,275)
OCA18. Characteristics of the output's impact on socio-economic practice	The work is focused towards anticancer effects of drugs and the search for their new targets. We have been dealing with this issue at the institute for a long time. This review article focuses on the heat shock protein HSP90, which is highly expressed in tumor cells and thus appears to be a new promising target for some drugs, including many substances of natural origin.
OCA19. Characteristics of the output and related activities' impact on the educational process	The anticancer drugs are part of lectures for medical students. For PhD students, the potential antitumor effect of natural substances is an important part of their studies. This work can help them understand the new targets for many of anticancer drugs.